5tca
From Proteopedia
(Difference between revisions)
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
==Complement Factor D inhibited with JH3== | ==Complement Factor D inhibited with JH3== | ||
| - | <StructureSection load='5tca' size='340' side='right' caption='[[5tca]], [[Resolution|resolution]] 3.15Å' scene=''> | + | <StructureSection load='5tca' size='340' side='right'caption='[[5tca]], [[Resolution|resolution]] 3.15Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5tca]] is a 7 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TCA OCA]. For a <b>guided tour on the structure components</b> use [ | + | <table><tr><td colspan='2'>[[5tca]] is a 7 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TCA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5TCA FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=J55:1-(2-{(2S)-2-[(6-BROMOPYRIDIN-2-YL)CARBAMOYL]-1,3-THIAZOLIDIN-3-YL}-2-OXOETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBOXAMIDE'>J55</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.15Å</td></tr> |
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=J55:1-(2-{(2S)-2-[(6-BROMOPYRIDIN-2-YL)CARBAMOYL]-1,3-THIAZOLIDIN-3-YL}-2-OXOETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-3-CARBOXAMIDE'>J55</scene></td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5tca FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tca OCA], [https://pdbe.org/5tca PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5tca RCSB], [https://www.ebi.ac.uk/pdbsum/5tca PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5tca ProSAT]</span></td></tr> | |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
== Disease == | == Disease == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/CFAD_HUMAN CFAD_HUMAN] Defects in CFD are the cause of complement factor D deficiency (CFDD) [MIM:[https://omim.org/entry/613912 613912]. CFDD is an immunologic disorder characterized by increased susceptibility to bacterial infections, particularly Neisseria infections, due to a defect in the alternative complement pathway. |
== Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/CFAD_HUMAN CFAD_HUMAN] Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to that of C1s in the classical pathway. |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 22: | Line 21: | ||
</div> | </div> | ||
<div class="pdbe-citations 5tca" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5tca" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Complement C3 3D structures|Complement C3 3D structures]] | ||
| + | *[[Complement factor 3D structures|Complement factor 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: | + | [[Category: Homo sapiens]] |
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: | + | [[Category: Stuckey JA]] |
| - | + | ||
| - | + | ||
Current revision
Complement Factor D inhibited with JH3
| |||||||||||
